Nevro (NYSE:NVRO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Nevro (NYSE:NVRO) in a report issued on Saturday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

Several other equities research analysts also recently commented on the company. Canaccord Genuity Group increased their price objective on Nevro from $4.00 to $5.85 and gave the company a “hold” rating in a report on Friday, February 7th. Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and increased their price objective for the company from $4.50 to $5.85 in a report on Monday, February 10th. Citigroup cut their price objective on Nevro from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, December 11th. Truist Financial cut their price objective on Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a report on Wednesday, December 18th. Finally, Piper Sandler raised Nevro from a “neutral” rating to an “overweight” rating and cut their price objective for the company from $6.00 to $5.85 in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.43.

Nevro Trading Down 0.1 %

NYSE:NVRO opened at $5.78 on Friday. Nevro has a twelve month low of $3.17 and a twelve month high of $14.70. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67. The business has a 50 day moving average price of $5.40 and a two-hundred day moving average price of $4.94. The company has a market cap of $221.60 million, a P/E ratio of -3.06 and a beta of 0.94.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Tuesday, March 4th. The medical equipment provider reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.15. The firm had revenue of $105.55 million during the quarter, compared to the consensus estimate of $102.61 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. As a group, analysts expect that Nevro will post -2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Amundi bought a new position in Nevro during the 4th quarter worth $30,000. Oxford Asset Management LLP bought a new position in Nevro during the 4th quarter worth $39,000. Virtu Financial LLC bought a new position in Nevro during the 3rd quarter worth $63,000. Corton Capital Inc. bought a new position in Nevro during the 4th quarter worth $43,000. Finally, Headlands Technologies LLC bought a new position in Nevro during the 4th quarter worth $45,000. Institutional investors own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.